Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Interaction Between Olanzapine and Pregabalin for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting-A Randomized Factorial Clinical Trial With Simulation.

Created on 20 Nov 2026

Authors

Mathan Kumar Ramasubbu, Archana Mishra, Milan Padhan, Priyanka Mukherjee, Rituparna Maiti, Debasish Hota, Saroj Kumar Das Majumdar, Dillip Kumar Parida, Anand Srinivasan

Published in

JCO oncology practice. Pages OP2500315. Nov 19, 2026. Epub Nov 19, 2026.

Abstract

In low- and middle-income settings where NK1 receptor antagonists are often unaffordable, we evaluated the interaction and efficacy of add-on olanzapine plus pregabalin for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
In this single-center 2 × 2 factorial, double-blind, add-on placebo-controlled trial, 104 participants receiving HEC were randomly assigned 1:1:1:1 to olanzapine 5 mg, pregabalin 75 mg, their combination, or placebo once daily for 4 days, with standard ondansetron and dexamethasone. The primary outcome was the olanzapine × pregabalin interaction on the mean 5-day Visual Analog Scale (VAS) nausea score. Secondary outcomes included no nausea, no significant nausea (VAS < 2.5), no vomiting, complete response/control, Functional Living Index-Emesis, and adverse events. Clinical-trial simulation explored the interaction at larger n and identified minimum effective doses.
No significant olanzapine × pregabalin interaction was detected on mean VAS (coefficient, 0.44 [95% CI, -0.89 to 1.77]; P = .52); effects were consistent with additivity at the trial sample size. Simulation at n ≥ 600 suggested a small antagonistic term, interpreted as hypothesis-generating. The combination arm had the lowest overall 5-day VAS (0.89, standard deviation [SD], 1.07) versus placebo (3.68, SD 2.06; analysis of variance P < .001); secondary outcomes favored the combination and are reported as hypothesis-generating. Emax modeling supports a future dose-reduced regimen of olanzapine 5 mg + pregabalin 50 mg once daily or olanzapine 2.5 mg + pregabalin 75 mg once daily to preserve efficacy while reducing toxicity. Sedation and dizziness were more frequent in the study-drug arms.
In patients receiving HEC, add-on olanzapine 5 mg + pregabalin 75 mg once daily improved nausea control versus placebo, with effects consistent with additivity. No synergy was demonstrated; the simulation-based antagonism signal warrants confirmation, and a dose-reduced combination is proposed for future evaluation.

PMID:
43056645
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement